Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Genomictree Inc. (228760:KRX), powered by AI.
Genomictree Inc. is currently trading at ₩12,720. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Genomictree Inc. on Alpha Lenz.
Genomictree Inc.'s P/E ratio is -35.2.
“Genomictree Inc. trades at a P/E of -35.2 (undervalued) with modest ROE of -7.5%.”
Ask for details →Genomictree Inc. is a biotechnology company specializing in the development of molecular diagnostics. The company's primary function is to create innovative diagnostics tools that aid in the early detection and prevention of various diseases, including cancer. Genomictree Inc.'s portfolio consists of proprietary biomarkers and assays that are applied in clinical settings to improve patient outcomes through precision medicine. The biotechnology sector, which includes pharmaceutical and healthcare industries, relies heavily on such advancements for personalized medicine approaches. Genomictree Inc. stands out in its field by leveraging state-of-the-art genomic technology, thus contributing significantly to the healthcare market's shift towards more targeted and effective diagnostic solutions. Based in South Korea, Genomictree Inc. is a key player in the regional market and demonstrates a growing influence internationally, fulfilling a crucial role in advancing global health diagnostics with its cutting-edge research and product development.
“Genomictree Inc. trades at a P/E of -35.2 (undervalued) with modest ROE of -7.5%.”
Ask for details →Genomictree Inc. (ticker: 228760) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 81 employees. Market cap is $316.2B.
The current price is ₩12,720 with a P/E ratio of -35.19x and P/B of 2.75x.
ROE is -7.52% and operating margin is -300.47%. Annual revenue is $3.8B.